NDC codes

414365 NDC codes with hospital pricing data in the network.

• NDC 13533-0705-01 — Alpha-1 proteinase inhibitor IV solutionAI (656 hospitals, 152,698–152,806 samples)
• NDC 00270-1315-45 — Iodinated contrast dye (Isovue-300 intravenous solution)AI (178 hospitals, 150,294–151,230 samples)
• NDC 13533-0705-11 — Alpha-1 proteinase inhibitor, human, 1,000 mg vialAI (350 hospitals, 150,884–150,938 samples)
• NDC 00270-1412-15 — Isovue-M 300 contrast dye injectionAI (608 hospitals, 136,139–150,908 samples)
• NDC 00270-7020-38 — Vueway MRI contrast dye, intravenous solutionAI (189 hospitals, 146,678–147,227 samples)
• NDC 50242-0260-01 — Pertuzumab and trastuzumab injection for under-the-skin useAI (707 hospitals, 144,809–145,205 samples)
• NDC 55135-0132-01 — Sacituzumab govitecan injection, 180 mg vialAI (895 hospitals, 142,034–142,646 samples)
• NDC 63323-0106-15 — Magnesium sulfate IV solution, 20 g in 500 mLAI (739 hospitals, 137,028–141,069 samples)
• NDC 52268-0100-01 — GoLYTELY oral bowel prep powderAI (1021 hospitals, 139,605–140,442 samples)
• NDC 51754-0108-03 — Tranexamic acid IV infusion in salineAI (533 hospitals, 137,073–138,468 samples)
• NDC 00409-0152-01 — Metronidazole intravenous solution 500 mg per 100 mLAI (523 hospitals, 136,419–137,202 samples)
• NDC 25021-0608-51 — Propofol intravenous emulsion, multiple vial sizesAI (432 hospitals, 133,709–136,256 samples)
• NDC 00270-1316-52 — Isovue-370 iodinated contrast injectionAI (244 hospitals, 131,352–132,828 samples)
• NDC 16714-0977-01 — PROPOFOL 10 MG/ML INTRAVENOUS EMULSIONAI (83 hospitals, 130,055–132,071 samples)
• NDC 08888-0044-87 — IOHEXOL 300 MG IODINE/ML INTRAVENOUS SOLUTION (5 hospitals, 131,325–131,460 samples)
• NDC 25021-0608-20 — Propofol injection, 200 mg per 20 mL vialAI (527 hospitals, 123,860–126,884 samples)
• NDC 67457-0422-54 — Dexamethasone sodium phosphate 20 mg/5 mL injectionAI (621 hospitals, 118,082–124,058 samples)
• NDC 00069-0209-10 — Propofol 200 mg/20 mL intravenous emulsionAI (446 hospitals, 101,605–121,504 samples)
• NDC 63323-0411-12 — Midazolam injection, 2 mg/2 mLAI (487 hospitals, 115,555–119,947 samples)
• NDC 00407-2223-19 — Visipaque 320 mg/mL intravenous contrast solutionAI (451 hospitals, 115,382–119,693 samples)
• NDC 00006-3061-00 — Fosaprepitant 150 mg single-dose vialAI (477 hospitals, 118,372–119,533 samples)
• NDC 76297-0001-42 — Sodium chloride 0.9% intravenous solutionAI (87 hospitals, 114,444–114,867 samples)
• NDC 63323-0286-23 — Naropin (ropivacaine) 5 mg/mL injectionAI (512 hospitals, 111,642–113,361 samples)
• NDC 00338-0433-04 — Heparin in sodium chloride premix, 1000 mLAI (296 hospitals, 109,538–111,698 samples)
• NDC 00023-6082-10 — Iron dextran injectionAI (839 hospitals, 108,862–111,175 samples)
• NDC 00338-0553-18 — Sodium chloride 0.9% IV solutionAI (746 hospitals, 97,957–110,908 samples)
• NDC 60505-6130-00 — Ondansetron 4 mg/2 mL injectionAI (636 hospitals, 95,836–109,975 samples)
• NDC 67457-0423-12 — Dexamethasone sodium phosphate 4 mg/mL injectionAI (954 hospitals, 85,022–108,548 samples)
• NDC 00009-0436-01 — Arginine hydrochloride intravenous solution, 10%AI (547 hospitals, 106,393–108,067 samples)
• NDC 65250-0266-09 — Exparel 1.3% injectable suspensionAI (669 hospitals, 105,531–107,196 samples)
• NDC 00409-1630-10 — Atropine sulfate 1 mg/10 mL injection syringeAI (615 hospitals, 103,893–105,360 samples)
• NDC 00409-4699-54 — Propofol intravenous emulsionAI (384 hospitals, 100,526–103,766 samples)
• NDC 00270-1316-04 — Isovue-370 iodinated contrast injectionAI (286 hospitals, 101,846–103,682 samples)
• NDC 00409-4755-03 — Ondansetron 4 mg/2 mL injectionAI (649 hospitals, 95,393–102,674 samples)
• NDC 79672-0613-04 — Normal saline infusion, 500 mL bagAI (50 hospitals, 99,365–99,581 samples)
• NDC 66975-0425-51 — Lidocaine with epinephrine numbing injectionAI (59 hospitals, 97,960–99,427 samples)
• NDC 44567-0707-25 — Cefazolin 1 gram injection solutionAI (675 hospitals, 93,975–99,384 samples)
• NDC 00409-4699-24 — Propofol intravenous emulsion, 1000 mg per 100 mLAI (619 hospitals, 91,661–99,194 samples)
• NDC 25021-0131-82 — Metronidazole 500 mg intravenous solutionAI (610 hospitals, 97,606–98,434 samples)
• NDC 00009-3073-23 — Methylprednisolone acetate injection 40 mgAI (185 hospitals, 96,565–97,330 samples)
• NDC 25021-0820-10 — Methylprednisolone acetate 40 mg/mL injectionAI (71 hospitals, 96,623–97,280 samples)
• NDC 00270-1315-50 — Isovue-300 contrast injection solutionAI (196 hospitals, 93,869–96,326 samples)
• NDC 00338-9543-02 — Intravenous 0.9% saline solutionAI (301 hospitals, 85,564–95,482 samples)
• NDC 55150-0167-10 — Bupivacaine local anesthetic injection, 0.25% solutionAI (801 hospitals, 83,892–94,764 samples)
• NDC 00338-0553-11 — Sodium chloride 0.9% intravenous solutionAI (637 hospitals, 85,022–94,544 samples)
• NDC 63323-0106-05 — Magnesium sulfate IV solutionAI (849 hospitals, 87,589–93,412 samples)
• NDC 00270-1315-95 — Isovue-300 contrast injection for imagingAI (242 hospitals, 89,827–93,229 samples)
• NDC 63323-0165-01 — Dexamethasone sodium phosphate 4 mg/mL injectionAI (1011 hospitals, 79,935–92,904 samples)
• NDC 00338-0072-25 — Ketorolac injection 30 mg per mLAI (657 hospitals, 85,558–92,893 samples)
• NDC 47335-0993-01 — Metronidazole 500 mg intravenous solutionAI (597 hospitals, 91,811–92,702 samples)